In healthy human pregnancies, placental growth factor (PGF) concentrations rise in maternal plasma during early gestation, peak over Weeks 26-30, then decline. Because PGF in nongravid subjects participates in protection against and recovery from cardiac pathologies, we asked if PGF contributes to pregnancyinduced maternal cardiovascular adaptations. Cardiovascular function and structure were evaluated in virgin, pregnant, and postpartum C56BL/6-Pgf
INTRODUCTION
Placental growth factor (PGF) is a member of the vascular endothelial growth factor (VEGF) family [1] with important cardioprotective roles [2] [3] [4] . PGF has prominent, specific roles in cardiac stress and disease that have made it an attractive therapeutic candidate [2, 3] . Research into infarcted and pressure-loaded hearts identified the importance of PGF in adaptive hypertrophy and in promotion of angiogenesis; PGF deficits in the diseased heart are strongly correlated with diminished prognosis for repair and survival [2] [3] [4] .
Pregnancy is physiologically challenging to the maternal cardiovascular (CV) system [5] . Typical pregnancy induces gains in blood volume [6] and cardiac output (CO), transient cardiac hypertrophy [6, 7] , and vessel restructuring across the decidualized endometrium. Decidual vascular restructuring includes early neoangiogenesis and later spiral arterial remodeling [8] , processes influenced by PGF [9, 10] . Plasma PGF concentrations fluctuate in women over pregnancy, increasing from the first trimester, peaking at 26-30 wk, and declining toward term [1, 11] . We postulated that gestational elevations in PGF participate in the normal functional adaptions of the maternal heart to pregnancy.
PGF executes its angiogenic properties primarily through binding with high affinity to VEGFR1 (also known as FLT1) [1] . VEGFA also binds to this receptor but with lower affinity and can be displaced by PGF. Displacement of VEGFA increases its bioavailability and ability to drive the major pathway for angiogenesis though binding to VEGFR2 [9, 12] . Humans have four PGF isoforms [12, 13] , whereas, mice express a single Pgf 2 gene homologue [14] . Pgf À/À mice have been available for a number of years. Because Pgf À/À 3 Pgf À/À matings produce viable litters containing normal numbers of pups [3, 9] , PGF has generally been considered redundant during development [14] . To address whether PGF has a role in maternal cardiac adaptations to pregnancy, we quantified PGF in the plasma of normal mice over pregnancy. Because the time course for the pattern of detection resembled that of human pregnancy, we proceeded to compare the CV systems of C57BL/6-Pgf À/À (Pgf
) females mated by Pgf À/À males to C57BL/6-Pgf þ/þ (B6) females mated by B6 males over pregnancy using plethysmography and ultrasound. These studies, supported by gross and histological studies of the maternal heart and kidney and by analysis of expression of targeted genes in the left ventricles (LVs) of late gestational females, implicate the dynamic, gestational elevation of PGF in maternal plasma in maternal CV adaptations to pregnancy.
MATERIALS AND METHODS

Experimental Animals
B6-Pgf
À/À mice were bred at Queen's University from foundation stocks provided by Peter Carmeliet [15] . Female and male B6 mice were purchased from Charles River Laboratories and used as controls. A total of 78 females (n ¼ 39 per genotype) were used in this study. Animal usage was conducted in accordance with the Society for the Study of Reproduction's specific guidelines and standards and under protocols approved by the Queen's University Animal Care Committee that were in accordance with the Canadian Council on Animal Care's Guide to the Care and Use of Experimental Animals.
At 11-16 wk of age, females were paired with a male. Detection of a copulation plug the following morning was considered Gestation Day 0 (gd0).
Enzyme-Linked Immunosorbent Assay
PGF-2 concentrations were measured by Quantikine enzyme-linked immunosorbent assay (ELISA) (R&D Systems) in undiluted, citrated plasma samples collected by cardiac puncture in anesthetized virgin, gestational daymatched, and Postpartum Day 30 (pp30) Pgf À/À and B6, using n ¼ 3-5 females/genotype/time point. Plasma samples were assessed as individual animals run in duplicate with means of the duplicates used for the analyses. The assay was performed according to manufacturer's instructions.
Arterial Pressure Recordings
Due to cerebral vascular complications that included an incomplete circle of Willis [16] , assessment of arterial pressure could not be conducted by radiotelemetry [17] . From a large study of Pgf À/À males and females on B6 and 129/SvJ strain backgrounds, only two 129/SvJ females were successfully recorded. These females mated, and their gestational recordings are included as Supplemental Figure S1 (Supplemental Data are available online at www. biolreprod.org) to support data on the impact of PGF deficiency collected by plethysmography. Baseline tail cuff recordings of systolic pressure were obtained (Coda High Throughput 4 chamber, Kent Scientific Corp.) from Pgf À/À (n ¼ 3) and B6 (n ¼ 4) females pretrained to the instrument for 14 days. Baseline pressure for each animal was averaged from 5-10 days of recordings after pretraining but prior to pregnancy. These females were subsequently mated, and their blood pressures were serially recorded on each day of pregnancy. Recordings included 25 cycles and machine acceptable measurements were subjected to outlier analyses, and the remaining values were averaged for each animal for each day and normalized to baseline values for statistical analysis.
Ultrasonography
The Vevo770 high-frequency ultrasound system (VisualSonics) was used to evaluate maternal CV function in anesthetized virgin and pregnant (gd8, 10, 12, 14, 16, and 18) Pgf À/À and B6 females (n ¼ 3-5 dams/genotype/time point). Each female was studied on only one gestational day (i.e., not followed serially) to permit postmortem collection of tissues that could be directly related to the sonographic findings. Animals were anesthetized using 5% inhaled isoflurane in oxygen and maintained at 1.5%-2% during sonography. The Vevo707B 30 MHz transducer was used for M-mode cardiac scanning to obtain structural and physiological data. Parasternal long axis views of the heart were used with the sample volume placed perpendicular to the aorta and through the LV at a midpapillary section to ensure consistency in measurement position between animals (Supplemental Fig. S2 ). The Vevo704 40MHz transducer was used to perform renal, uterine, and umbilical arterial scans. Pulsed-wave Doppler measurements were obtained using an angle of insonation of less than 608 from uterine and renal arteries. Renal artery resistance index (RI) was calculated as RI ¼ (peak systolic velocity À end diastolic velocity)/peak systolic velocity. Between gd10 and gd18, as permitted by litter size and fetal development, three to five fetuses from each dam were located, and fetal heart rates, umbilical artery peak velocities, and umbilical artery RI were measured.
Postmortem Organ Wet Weights
Following the ultrasonographic study, the animals were euthanized by sodium pentobarbitol overdose (CEVA Sante Animale) (50 mg/kg), exsanguinated by cardiac puncture, and dissected. Hearts were removed and weighed intact. The heart chambers were then dissected, weighed individually, and snap frozen in liquid nitrogen for gene expression studies. Right hind limbs were dissected, digested overnight in 0.2 M NaOH at 608C and then tibia length was measured using digital calipers. Tibia lengths were constant during pregnancy and did not differ between genotypes (P ¼ 0.17) and, therefore, were used for normalization of heart weight to body size of each mouse. Both kidneys were freed of adhering adipose tissue and weighed. Fetal weights were obtained after removal of the amniotic sac, placenta, and umbilical cord. Live pup weights were obtained on pp4, prior to euthanasia.
Histological and Morphometric Analyses
A separate cohort of virgin and gd16 Pgf À/À and B6 mice (n ¼ 3/genotype/ time point) was used exclusively for histological studies. These mice were euthanized and perfusion-fixed (transcardiac) with potassium-based perfusion buffer (140 mM NaCl, 10 mM KCl, 5 mM ethylenediaminetetraacetic acid) [18] for 5 min (1 ml/min) followed by 4% neutral buffered paraformaldehyde for 5 min (1 ml/min) using a constant flow pump. Hearts and right kidneys were then removed, further fixed by overnight immersion in paraformaldehyde, then processed for paraffin embedding. Parasternal short-axis cardiac (6 lm) and coronal renal sections (2 lm) were cut and stained with hematoxylin and eosin. Sections were digitized and analyzed using standard light microscopy and Zeiss AxioVision Software. For each heart, maximum LV chamber area and exterior wall thickness were measured. For each kidney, 10 randomly selected renal corpuscles were identified and photographed. Surface areas of each corpuscle and glomerulus were measured. Subtraction of the latter was used to estimate Bowman space. Glomerular cellularity was estimated by counting endothelial cell numbers.
Immunohistochemistry (IHC) for NOS2 and NOS3 was performed on a second cohort of perfusion-fixed B6 and Pgf À/À hearts at virgin, gd8, and gd14. Paraffin-embedded hearts were cut at 6 lm and a diaminobenzidine chromogen protocol was used. Slides were incubated with 3% bovine serum albumin buffer (0.03 g bovine serum albumin in 10 ml Tris-buffered saline), and antigen retrieval was performed using citrated buffer (1.92 g citric acid, 0.74 g ethylenediaminetetraacetic acid, 1000 ml water, 0.5 ml tween 20) under humid conditions for 30 min. Primary antibodies were purchased from Abcam (rabbit polyclonal antibody against iNOS; 1:200 dilution) and Santa Cruz Biotechnologies (rabbit polyclonal antibody against eNOS; 1:100 dilution). Secondary antibody used for both (biotinylated goat anti-rabbit immunoglobulin G, 1:200 dilution) was purchased from Vector Laboratories. Sections were counterstained with hematoxylin. Negative control consisted of an isotype control in place of primary antibodies; no staining resulted. Image analysis was performed by pixel quantification using image analysis software (GIMP 2.8.10).
Real-Time Quantitative PCR
Total RNA was extracted from snap-frozen LV samples from virgin, gd8, and gd14 females (previously used for ultrasound studies) using the high-pure tissue RNA isolation kit (Roche Scientific Co.) and an established, modified protocol [19] . Reverse transcription of total RNA was then performed using a high-capacity cDNA reverse transcription kit (Applied Biosystems) following the manufacturer's instructions. Relative mRNA expression was measured in triplicate and means reported relative to Gapdh mRNA using quantitative PCR (qPCR) (Roche Lightcycler 480 II). Primers were designed using published GenBank sequences and Primer Designer Software version 2.01 (Scientific and Educational Software). Primer sequences and standard curve efficiencies are given in Supplemental Table S1 .
Statistical analyses
Statistical analysis was performed using Prism 5.0 Statistical Software (GraphPad). PGF ELISA analysis in detectable mice (B6 only) was performed using one-way ANOVA; differences between gestational days were determined by Tukey posttest. Comparisons between Pgf À/À and B6 genotypes across gestation were performed using two-way ANOVA, and differences at specific gestational days were tested using Bonferroni posttest and comparisons setup as Pgf À/À versus B6. Data are presented as mean 6 standard error (SEM), using n ¼ 3-5 dams/group. Differences were defined as significant at P 0.05. Regression analysis was used to determine differences in changes over time, with a significantly nonzero slope considered a change. Morphometric analysis between groups (virgin vs. gd16) was performed using Student t-test.
RESULTS
Maternal Plasma PGF Concentrations Fluctuate over Gestation
Plasma PGF levels were measured in virgin, pregnant, and pp30 Pgf À/À and B6. PGF was not detected in any Pgf
sample. PGF levels in virgin and postpartum B6 were detectable but very low; significantly higher levels were detected in all pregnant B6 samples. PGF concentrations rose to gd10-14 (statistically similar) then declined. PGF concentrations in B6 females were highest at gd10; this was the only time point that showed a statistically significant increase from AASA ET AL.
virgin levels. Levels at gd10 were not significantly higher than levels at gd14; however, levels were higher than all other time points measured (Fig. 1) .
Arterial Pressure over Gestation
In virgin Pgf
, systolic arterial pressure (SAP) was elevated relative to B6 females ( Fig. 2A) . This was also true in late gestation ( Fig. 2A) . However, the overall pattern of change in Pgf À/À SAP was similar to B6, that is, SAP dropped from preconception baseline after gd6 with a gd9 nadir. B6 recovery to baseline pressure was achieved by gd12 but was delayed in Pgf À/À . Differences in SAP (delta from baseline) over pregnancy increased in a nonstatistically significant manner in Pgf À/À compared to B6 dams (P ¼ 0.055, Fig.  2B ). When raw data were segregated into previously determined phases of embryonic and placental development thought to influence blood pressure [17] , differences between groups were significant in phase 1 (gd0-5, extent of the drop in SAP) and phase 4 (gd15-18, extent of the rebound) (P ¼ 0.0002 and P ¼ 0.047, respectively). In both phases, Pgf À/À dams had higher SAP than B6 ( Fig. 2A) . Duration of the hypotensive phase was longer in Pgf À/À dams than the single day nadir in B6 ( Fig. 2B ).
Echocardiographic Evaluation of Cardiac Function
Echocardiographic analyses in virgin Pgf
À/À and B6 mice showed no functional differences. In pregnant Pgf À/À females, CO and stroke volume (SV) were stable while in pregnant B6 females CO and SV increased over gestation, as expected for a normal pregnancy (Fig. 2, C and D) . Cardiac output was reduced overall in Pgf À/À dams across pregnancy compared with B6 (P ¼ 0.008); significance at specific time points was found at gd14 and gd16 (Fig. 2C) . Overall SV during pregnancy was also smaller in Pgf À/À dams compared to B6 (P ¼ 0.005), reaching a specific time point statistical significance at gd16 (Fig. 2D ).
Echocardiographic and Postmortem Assessment of Cardiac Structure
There were no statistical differences between Pgf À/À and B6 heart or LV weights for virgin animals ( Fig. 3A-C) . Echocardiography did not detect any change in Pgf À/À LV mass over pregnancy while LV mass increased from virgin levels over gestation in B6 (Fig. 3A) .
Postmortem studies of hearts collected at each study time point supported the echocardiographic data. When normalized to tibia length, Pgf À/À LV wet weight did not change over gestation while B6 LV wet weight increased from its virgin level over gestation (Fig. 3B) . Overall differences in normalized LV mass throughout pregnancy and postpartum between Pgf À/À and B6 mice were not significant (P ¼ 0.088, Fig. 3B ). Normalized total heart weight increased over gestation and postpartum only in B6 (Fig. 3C ). Lack of PGF had an effect on total heart weight with Pgf À/À hearts being heavier than B6 over virgin, pregnancy, and postpartum time points (P ¼ 0.049); analysis of individual pregnancy time points did not show statistical differences between genotypes (P ¼ 0.089, Fig.  3C ).
Virgin Pgf À/À and virgin B6 LVs appeared structurally similar by routine histological examination (Supplemental Fig.  S3 ). Morphometric studies looking at wall width and chamber size at gd16 (when cardiac functional differences were seen sonographically) suggested that Pgf À/À LVs were not different from B6 (P ¼ 0.16; data not shown).
LV Gene and Protein Expression
Real-time qPCR analysis for LV relative expression of the natriuretic peptide and VEGF gene systems (Nppa, Nppb, Npra, Nprc, Vegfa, Vegfb, Vegfr1, Vegfr2) found no differences between Pgf À/À versus B6 in virgin, gd8, or gd14 animals (data not shown). Relative Eng expression across all the samples was greater in Pgf À/À LV versus B6 across gestation but did not reach significance at any specific time point studied (Fig. 4A) . Genotype had an effect on overall Nos3 relative expression, with greater expression in Pgf À/À LV. Time point-specific differences in Nos3 were present in gd8 but not virgin or gd14 Pgf À/À versus B6 LV (Fig. 4B) . PGF deficiency had a similar gestation day-specific effect on relative Nos2 expression, being higher only in gd8 Pgf À/À LV. The effect of genotype on overall relative Nos3 expression showed a nonsignificant increase in Pgf À/À LV (P ¼ 0.09; Fig.  4C ). These dynamic expression patterns were confirmed using IHC (Fig. 4D-G) .
Renal Analyses in Virgin and Pregnant
Renal artery RI, used to measure downstream vascular impedance, did not differ between virgin Pgf À/À versus B6. Gestational renal artery RI in Pgf À/À was also not statistically different versus B6 (P ¼ 0.11, Fig. 5A ). Postmortem kidney weights normalized to tibia lengths were greater in Pgf À/À than in pregnancy status-matched B6 (P ¼ 0.036, Fig. 5B ). Renal histopathology (Fig. 5C ) at gd16 quantified glomerular hypercellularity and depleted urinary spaces in Pgf À/À versus B6 kidneys (P , 0.001, Fig. 5, D and E) .
Fetal Outcomes in Pgf
À/À Pregnancy Uterine artery RI was elevated in Pgf À/À versus B6 dams across gestation (Fig. 6A) but not at any specific gestation day. Fetal heart rates however did not differ between genotypes (Fig. 6B) . Umbilical artery RI was also similar between FIG. 1. Circulating PGF concentrations in B6 mice using ELISA (n ¼ 3-5 pregnancies/time point). PGF was below detectable levels in all Pgf À/À dams (not shown). PGF concentrations in B6 females peaked at gd10, the only time point that showed a significant difference from virgin levels. Levels at gd10 were not significantly higher than levels at gd14, but were higher than all other time points measured. Significance determined by one-way ANOVA with Tukey posttest. *P 0.05 from gd10, **P 0.001 from gd10.
PGF AFFECTS GESTATIONAL CARDIOVASCULAR ADAPTATION genotypes (Fig. 6C) as were intrapartum and postpartum litter sizes (Fig. 6D) . Pgf À/À fetuses weighed less than B6 fetuses at both gd14 and gd18. This difference did not persist postpartum with pup weights measured as equivalent at pp4 (Table 1) . These differences between groups in fetal and postnatal offspring weights were not associated with differences between genotypes in maternal body weight across pregnancy (Supplemental Table S2 ).
DISCUSSION
This study provides the first thorough physiological assessment of the effect of PGF deficiency on mouse pregnancy. We postulated that the high PGF concentrations that develop in the plasma of pregnant women between early pregnancy and wk 30 may contribute to the maternal CV adaptations necessary for support of conceptus growth and pregnancy success. Our comparisons between Pgf À/À and B6 pregnancies document an involvement of PGF in the normal cardiac adaptations that occur during mid-to late pregnancy [20] . We found that by gd8 PGF concentrations in B6 maternal plasma were elevated over preconception values. Peak levels were found over gd10-14, after which PGF levels dropped and had returned to baseline at pp30. This pattern reflects the Pgf À/À gene expression time course measured previously in decidua basalis [9] and is generally similar to that seen in human pregnancy. The pattern of mouse PGF fluctuation was coordinated with various maternal cardiac changes measured over normal B6 pregnancy. Cardiac functional parameters,
FIG. 2. Systolic arterial pressure (SAP) (A and B) was analyzed in trained Pgf
À/À and control females across gestation using tail cuff plethysmography (n ¼ 4 B6, n ¼ 3 Pgf
À/À
). A) Raw SAP over pregnancy was divided into phases according to typical blood pressure fluctuations in normal mouse pregnancy (29) . In phase 1 (gd0-5) and phase 4 (gd15-18), SAP was higher in Pgf À/À than B6 dams. Baseline (prepregnancy) values are indicated for Pgf À/À (horizontal dotted line) and B6 (horizontal solid line). Prepregnancy SAP was higher in Pgf À/À versus control females. B) SAP was normalized to baseline values and represented as a change from baseline over pregnancy. Fluctuations in SAP in Pgf À/À dams appear to follow the same trends as B6 dams, however, the magnitude of fluctuations appear more pronounced. The nadir appearing at gd9 in control mice appears to be prolonged to several days in Pgf À/À (A and B). PGF-related functional adaptations of the maternal heart. Maternal cardiac systolic function (B and C) was assessed using echocardiography (n ¼ 3-5/ group/time point). C) Cardiac output (CO) increases over gestation in B6 dams but not Pgf À/À dams (by linear regression). PGF has an effect on CO in pregnancy, with decreased CO seen in Pgf À/À females, reaching significance at gd14 and gd16. D) Stroke volume (SV) increases across gestation only in B6 dams (by linear regression). SV is lower overall in Pgf À/À females; differences at specific gestational days were reached at gd16. Changes over time were determined by linear regression with a statistically nonzero slope (C and D). Differences between groups were determined by two-way ANOVA with Bonferroni posttest (A-D). *P 0.05, **P 0.01, ***P 0.001 versus age-matched B6.
AASA ET AL. such as CO and SV, peaked during midgestation (gd10-14). Similarly, structural parameters, such as LV mass, reached peak levels during midgestation.
In humans, maternal plasma PGF deficiency is linked to the hypertensive disorder preeclampsia and fetal growth restriction [21] [22] [23] . However, neither the effects of PGF on regulation of maternal blood pressure nor the roles of PGF in fetal development and growth are known. We evaluated both features in Pgf À/À mice that were confirmed by ELISA and PCR to be PGF deficient. Although radiotelemetric studies are regarded as the optimal approach for blood pressure studies in rodents [24] and were attempted, they could not be conducted in Pgf À/À mice due to cerebral vascular anomalies, including an incomplete circle of Willis in .80% of adult Pgf À/À females and males [16] . We therefore used plethysmography to assess the impact of PGF deficiency on gestational blood pressure. The key findings in Pgf À/À dams were that preconception SAP was higher and that the pregnancy-induced drop in SAP (between gd6 and gd9) was extended in length. Once Pgf À/À SAP returned to baseline (gd14), it differed from B6 by being unstable and dropping between gd16 and term. These measurements suggest an association of PGF with fine control of gestational blood pressure and with the normal, midgestational rebound in mean arterial pressure [17, 25] . The normal midgestational ascent of mean arterial pressure from nadir in normal mice occurs at the same time as completion of placental development, opening of the placental circulation, and intraluminal invasion of trophoblasts [17, 26] . Differences in SAP were also present between gd0 and gd5, with Pgf À/À dams having higher SAP than B6. A similar finding that PGF levels inversely correlate with maternal blood pressure was reported in a prospective study of 110 women in first trimester [27] . Both the mouse and human data attribute significance to the small elevations in plasma PGF that occur very early in pregnancy. SAP was elevated in Pgf À/À dams versus controls in late pregnancy (gd15-18). This phase immediately follows normal peak PGF levels in pregnancies. We postulate that differences in cardiac function between groups at gd14 and gd16 has systemic consequences that are reflected as changes in blood pressure by phase 4 of pregnancy. Baseline (prepregnancy) SAP appeared higher in Pgf À/À females but did not reach statistical significance.
An important component of blood pressure regulation is the kidney. Both PGF and VEGF are linked to renal development and function and glomerular podocytes are known to express PGF [28] . Renal hypertrophy, glomerular hypercellularity, and diminished urinary space were seen in Pgf À/À compared to B6 kidneys in late pregnancy. The elevated systolic pressures during early and late Pgf À/À pregnancy could either contribute to or result from the renal hypertrophy observed in pregnant Pgf À/À females. Prior to conception, Pgf À/À hearts did not differ statistically from B6 hearts in any parameter measured. This supports previously published data that Pgf À/À mice, prior to any intervention, have no cardiac phenotype [29] . Increases in CO and SV characterize normal pregnancy in mice and women [30, 31] . These pregnancy-induced CV stressors bear similarities to other CV stressors, such as pressure overload or myocardial infarct [ 2, 3, 29, 32, 33 ]. In these latter conditions, PGF administration decreases heart failure incidence and amelio- FIG. 3 . PGF deficiency is accompanied by cardiac structural differences across pregnancy and postpartum. A) Left ventricular (LV) mass, determined by echocardiography (n ¼ 3-5/group/time point), increased over gestation in B6 but not Pgf À/À dams. Total heart wet weight and chamber weights were determined at euthanasia (n ¼ 3-5/group/time point, B and C). Weights were normalized to tibia length (unchanged between groups, P ¼ 0.17) to account for differences in body weight initially and over the course of pregnancy (B and C). B) Normalized LV mass appeared increased in Pgf À/À dams compared to controls across pregnancy and postpartum, but the difference was not significant (P ¼ 0.088). C) Normalized heart mass was greater in Pgf À/À versus B6 dams throughout pregnancy and postpartum (P ¼ 0.049), but the differences did not reach significance at any specific time point. Changes over time were determined by linear regression with a statistically nonzero slope (A). Differences between groups were determined by two-way ANOVA with Bonferroni posttest (B and C).
PGF AFFECTS GESTATIONAL CARDIOVASCULAR ADAPTATION
FIG. 4. Upregulated gene expression in left ventricular (LV) tissue of Pgf
À/À mice at midgestation. Messenger RNA expression was determined using qPCR and normalized to expression of Gapdh (n ¼ 4/group/time point, A-C). Differences in LV NOS2 and NOS3 protein levels were measured by IHC (D-G). A) Relative endoglin (Eng) expression was increased overall compared to B6 controls (P ¼ 0.039) but did not reach significance at any specific time point. B) Relative Nos3 (eNOS) expression was increased in Pgf À/À LV compared to B6. Differences were significant at gd8. C) Relative LV Nos2 (iNOS) expression was increased in Pgf À/À compared to B6 only at gd8. D) NOS3 protein expression showed a nonstatistically significant increase in Pgf À/À LV compared to B6 overall (P ¼ 0.09); gestation day-specific differences reached significance at gd8 (P , 0.01). E) NOS2 protein expression was also AASA ET AL.
rates recovery by increasing cardiac angiogenesis and promoting adaptive hypertrophy. The gd16 Pgf À/À hearts phenotypically resembled pressure-overload hearts, being enlarged by weight but having a similar ventricular wall thickness as controls [2, 3, 29, [32] [33] [34] [35] . The most pronounced cardiac differences between pregnant Pgf À/À and B6 dams were in CO and SV at gd14 and gd16, days following the highest circulating concentrations of PGF in normal pregnant mice. We suggest this reflects a delay in adaptation to PGF deficiency and indicates a role for PGF in maternal cardiac remodeling over midpregnancy. Normalization of these parameters by gd18 in Pgf À/À dams corresponds with the decrease in circulating PGF levels of normal pregnancy and suggests a limited window for PGF activity during gestational CV adaptations. Dilatory growth is a possible explanation for the failure of CO and SV to increase across Pgf À/À gestations. Cardiac stress alters expression levels of many genes [36, 37] . Members of the NOS gene system are prominent amongst the genes altered during cardiac stress and, like PGF, participate in cardioprotection, the hypertrophic response, and angiogenesis [34, 36, 38, 39] . In mice, overexpression of Pgf increases LV Nos3 expression and NO production, steps pivotal to downstream cardiomyocyte hypertrophy [34] . Upregulation of Nos3 by pregnancy in Pgf À/À LV must be mediated via another, as yet undefined pathway. Both PGF and NOS3 increase adaptive hypertrophy in a cardioprotective manner; however, NOS3 (through NO) also has strong vasodilatory properties. This may contribute to the development of a more dilatory hypertrophy in the hearts of late FIG. 5 . Renal hypertrophy and structural abnormalities are present in pregnancies lacking PGF. A) Renal artery RI in Pgf À/À versus B6 did not reach a statistically significant difference (n ¼ 3-5/group/time point, P ¼ 0.11). B) Total kidney wet weight was measured at euthanasia and normalized to tibia length (n ¼ 3-5/group/time point). Kidney weight increased in Pgf À/À dams over pregnancy and postpartum compared to B6 controls (P ¼ 0.0015). Differences at specific gestational days reached significance by Postpartum Day 30 (pp30). C) Representative sections from nonpregnant (NP) and gd16 Pgf À/À and B6 dams. D) Bowman capsular space (urinary space) was measured in randomly selected cortical glomeruli by subtracting glomerular area from total corpuscle surface area (n ¼ 3/group/time point). Urinary space was significantly decreased in Pgf À/À kidneys versus controls. E) Cellularity was measured in 10 random glomeruli; cellularity was increased in gd16 Pgf À/À versus B6 kidneys. Bars ¼ 20 lm (C). Differences between groups were determined by two-way ANOVA with Bonferroni posttest (A and B). Differences in urinary space and glomerular cellularity at gd16 were determined by Student t-test (D and E). ***P 0.0001.
increased in Pgf
À/À LV tissue versus B6 control both overall (P , 0.0001) and at gd8 (P , 0.001). F and G) Representative micrographs from virgin, gd8, and gd14 Pgf À/À and B6 LV showing IHC staining for NOS3 and NOS2 with hematoxylin counterstain. Quantitative differences in IHC staining were determined by relative pixel density. Inlets represent negative isotype control (F and G). Differences between groups determined by two-way ANOVA with Bonferroni posttest (A-C). *P 0.05. **P 0.01, ***P , 0.001. Bars ¼ 20 lm.
PGF AFFECTS GESTATIONAL CARDIOVASCULAR ADAPTATION gestational Pgf
À/À dams. Much like NOS3, NOS2 has cardioprotective effects [40] , and increased NOS2 levels are a downstream, compensatory effect of the increased systolic pressure in Pgf À/À early pregnancy [41] . Exaggerated fluctuations in blood pressure across pregnancy in Pgf À/À dams and their diminished ability to quickly rebound from the midgestation nadir may contribute to altered Nos2 expression. Nos2 and Nos3 expression in the heart appear to be inversely correlated with blood pressure in Pgf À/À dams at midgestation. The extended nadir in systolic pressure in Pgf À/À dams may result from the vasodilatory outcomes from increased Nos expression [42] , however, this is yet to be addressed experimentally.
PGF deficiency and its associated maternal CV alterations were of limited impact on fetal blood flow and growth. Increased uterine artery RI in Pgf À/À dams indicated an increase in downstream vascular impedance [43] . PGF is known to contribute to uterine artery vasodilation, and these effects are pronounced in pregnancy [14] ; in this way, PGF contributes to uterine artery remodeling in response to pregnancy [44] . Spiral artery modification is only slightly delayed in pregnant Pgf À/À versus B6 females [9] , suggesting that spiral arteries are not the cause of the impedance we observed. Intrapartum death was not elevated in Pgf À/À litters, and fetuses had normal heart rates and umbilical flow velocities. However, late gestational Pgf À/À fetuses were lighter than controls, suggesting that PGF-driven angiogenesis may contribute directly to fetal growth rates, rather than through measurable circulatory parameters. Normalization of offspring weight by Postnatal Day 4 suggests acquisition of an additional CV risk factor because rapid postnatal growth after slower than normal fetal growth is associated with subsequent CV and metabolic diseases [45] [46] [47] . Thus, while PGF appears redundant for fetal development, the high levels of PGF found in maternal plasma during normal pregnancy are associated with protective functions on the maternal CV system across midgestation. The late pregnancy decline in maternal plasma PGF may reflect completion of the major steps of maternal cardiac and vascular remodeling needed to support the latest stages of pregnancy.
This study reveals novel associations between PGF levels and normal maternal CV adaptations to pregnancy. Continued efforts to stratify pregnant women who go on to develop pregnancy complications into those with low or with normal levels of PGF are warranted. This will enable refined evaluations of the exact role of PGF in the disturbed CV adaptations seen in pregnancy complications. Further evalua- 
fetuses/dam) (A-C). A) Uterine RI is increased in Pgf
À/À dams compared to B6 across gestation (P ¼ 0.013) but did not reach significance at any specific gestational days. B) Fetal heart rate was measured between peaks on pulsed-wave Doppler cine loops of the umbilical artery. Fetal heart rate did not differ between genotypes at any gestational time point measured. BPM, beats per minute. C) Umbilical artery RI did not differ between genotypes across gestation. D) Litter size did not differ between Pgf À/À and B6 pregnancies. Differences between groups were assessed by two-way ANOVA with Bonferroni posttest (A-D). AASA ET AL.
tions may also shed light on the role of PGF in subsequent maternal CV risk after a complicated pregnancy [48] .
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